Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...

Sisense, the leader in AI-driven analytics that transforms enterprise data into a competitive edge, today announced Sisense Intelligence, a comprehensive suite of AI-powered tools that empowers ...

Itepekimab, developed by Sanofi and Regeneron, met its primary endpoint in the AERIFY-1 phase 3 study for COPD, showing a 27% reduction in modera ...

For example, the Boehringer Ingelheim Cares Foundation PAP helped more than 69,000 patients in 2011. 5 Partnership for Prescription Assistance, sponsored by America's biopharmaceutical research ...

Supported by Boehringer Ingelheim. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank Florian Voss, of Boehringer Ingelheim ...

A Hartford community member advocates for local mental health crisis facilities, highlighting gaps in care for those ...

That treatment is personalized to each patient and might come in several forms, such as hormone therapy, chemotherapy or radiation. The fact that Biden’s cancer has spread to the bone “is very ...

While Eli Lilly does not offer a patient assistance program for those without insurance, there is a Mounjaro Savings Card program to help certain people with commercial insurance get the drug even ...

Many organizations help patients pay for cancer treatment, medication, and other expenses. Fred Hutch Cancer Center offers financial assistance to patients based on family need. Low-income patients ...

The main outcome focused on seven key dialysis facility quality measures, including hospitalization ratios and patient experience ... “This could come in the form of more stringent quality ...

NEW JERSEY, NJ, UNITED STATES, May 26, 2025 /EINPresswire.com/ -- The global biosimilars market is experiencing robust growth as healthcare systems strive to improve patient access to life-saving ...

SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that ...